Chapter

Imaging Applications to Parkinson’s Disease Clinical Trials

Martin Niethammer and Andrew Feigin

in Imaging in Parkinson’s Disease

Published in print September 2011 | ISBN: 9780195393484
Published online September 2011 | e-ISBN: 9780199914494 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780195393484.003.0119
Imaging Applications to Parkinson’s Disease Clinical Trials

Show Summary Details

Preview

This chapter reviews the role of neuroimaging in PD clinical trials to investigate both symptomatic and potential disease-modifying therapies. While clinical ratings are typically used as the primary measures of therapeutic response, these descriptors have inherent limitations. Imaging methods including FDOPA PET and beta-CIT SPECT have been used to provide objective and potentially less variable indicators of treatment outcome. The chapter describes the relevance of imaging biomarkers to trial design, including confirmation of diagnosis prior to randomization and as an adjunctive means for assessing efficacy. This chapter reviews the use of functional brain imaging in prior clinical trials of PD and discusses novel applications of these tools in the evaluation of new therapies for the disorder.

Keywords: clinical trials; Parkinson’s disease; biomarker; treatment outcome; neuroimaging; FDOPA PET; Beta-CIT SPECT

Chapter.  6645 words.  Illustrated.

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.